ABVC BioPharma, Inc. Payments to Acquire Long-term Investments
ABVC BioPharma, Inc. (ABVC) reported Payments to Acquire Long-term Investments of $668.40 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLongtermInvestments · last filed 2026-08-12
- ABVC BioPharma, Inc. payments to acquire long-term investments for the quarter ending 2026-06-30 was -$11.60K.
- ABVC BioPharma, Inc. payments to acquire long-term investments for the quarter ending 2026-03-31 was $680.00K.
- ABVC BioPharma, Inc. payments to acquire long-term investments for the quarter ending 2023-12-31 was -$154.17K, a 285.31% decline year-over-year.
- ABVC BioPharma, Inc. payments to acquire long-term investments for the quarter ending 2023-09-30 was $52.58K.
- ABVC BioPharma, Inc. payments to acquire long-term investments for fiscal 2023 was $338.99K, a 78.84% decline from fiscal 2022.
- ABVC BioPharma, Inc. payments to acquire long-term investments for fiscal 2022 was $1.60M, a 135.27% increase from fiscal 2021.
- ABVC BioPharma, Inc. payments to acquire long-term investments for fiscal 2021 was $680.92K.
| Period end | Payments to Acquire Long-term Investments 3 month | Payments to Acquire Long-term Investments 6 month | Payments to Acquire Long-term Investments 9 month | Payments to Acquire Long-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $668.40K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $680.00K 10-Q · filed 2026-05-18 | |||
| 2023-12-31 | -$154.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$101.59K derived: sum of 2 quarters · filed 2025-04-15 | $338.99K 10-K · filed 2025-04-15 | |
| 2023-09-30 | $52.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $493.16K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $440.57K 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $83.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.60M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $1.52M 10-Q · filed 2023-11-15 | |||
| 2021-12-31 | -$423.69K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $258.94K derived: sum of 2 quarters · filed 2023-03-31 | $398.96K derived: sum of 3 quarters · filed 2023-03-31 | $680.92K 10-K · filed 2023-03-31 |
| 2021-09-30 | $682.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $822.66K derived: sum of 2 quarters · filed 2022-11-14 | $1.10M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $140.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $421.97K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $281.95K 10-Q · filed 2022-05-16 |